MR spectroscopy in schizophrenia

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 6, 2011, Pages 1251-1261

  Port, John D ^a   Agarwal, Nivedita ^b,c  

^a MAYO CLINIC   (United States)

^b Department of Radiology   (Italy)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

GABA; glutamate; metabolites; MR spectroscopy; neural circuitry; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; CREATINE PHOSPHATE; DNA METHYLTRANSFERASE 1; DOPAMINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GLYCINE TRANSPORTER INHIBITOR; LAMOTRIGINE; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NAPHTHALENE; PROTEIN INHIBITOR; REELIN; TOPIRAMATE; UNCLASSIFIED DRUG;

ANTERIOR CINGULATE; ASTROCYTE; BASAL GANGLION; BIOCHEMISTRY; BRAIN CORTEX; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL FEATURE; DISEASE COURSE; GRAY MATTER; HIPPOCAMPUS; HUMAN; MEMORY; META ANALYSIS (TOPIC); METABOLITE; NEGATIVE FEEDBACK; NERVE CELL; NERVE CELL PLASTICITY; NEUROANATOMY; NEUROIMAGING; NONHUMAN; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW (TOPIC); TEMPORAL LOBE;

ASPARTIC ACID; GAMMA-AMINOBUTYRIC ACID; GLUTAMATES; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA;

EID: 81755177861     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22787     Document Type: Review

References (79)

1. Kasai K, Iwanami A, Yamasue H, Kuroki N, Nakagome K, Fukuda M,. Neuroanatomy and neurophysiology in schizophrenia. Neurosci Res 2002; 43: 93-110.
2. Lewis DA, Lieberman JA,. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28: 325-334.
3. van Os J, Kapur S,. Schizophrenia. Lancet 2009; 374: 635-645.
4. Picchioni MM, Murray RM,. Schizophrenia. BMJ 2007; 335: 91-95.
5. Lewis DA, Sweet RA,. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest 2009; 119: 706-716.
6. Akbarian S,. Epigenetics of schizophrenia. Curr Top Behav Neurosci 2010; 4: 611-628.
7. Veldic M, Kadriu B, Maloku E, et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res 2007; 91: 51-61.
8. Carlborg A, Winnerback K, Jonsson EG, Jokinen J, Nordstrom P,. Suicide in schizophrenia. Expert Rev Neurother 2010; 10: 1153-1164.
9. Golgi C,. Sulla struttura della sostanza grigia dell cervello. Gazz Med Lombarda 1873; 33: 244-246.
10. Ramõn y Cajal S,. Histologie du système nerveux de l' homme et des vertébrés. Tome I. Paris: Malone; 1909.
11. Ramõn y Cajal S,. Histologie du système nerveux de l' homme et des vertébrés. Tome II. Paris: Malone; 1911.
12. Ramõn y Cajal S, Azoulay L,. Les nouvelles idées sur la structure du système nerveux chez l'homme et chez les vertébrés Paris: C. Reinwald; 1894.
13. von Waldeyer-Hartz HWG,. Ueber einige neuere Forschungen im Gebiete der Anatomie des Centralnervensystems. Deutsche medicinische Wochenschrift 1891; 17: 1213-1218, 1244-1246, 1287-1289, 1331-1332, 1350-1356.
14. Zilles K, Amunts K,. Centenary of Brodmann's map-conception and fate. Nat Rev Neurosci 2010; 11: 139-145.
15. Brodmann K,. Vergleichende Lokalisationslehre der Grosshirnrinde in ihren Prinzipien dargestellt auf Grund des Zellenbaues. Leipzig: JA Barth; 1909. x, 324 p.
16. Mountcastle VB,. Modality and topographic properties of single neurons of cat's somatic sensory cortex. J Neurophysiol 1957; 20: 408-434.
17. Grinvald A, Slovin H, Vanzetta I,. Non-invasive visualization of cortical columns by fMRI. Nat Neurosci 2000; 3: 105-107.
18. Akbarian S, Huang HS,. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 2006; 52: 293-304.
19. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA,. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A 1998; 95: 5341-5346.
20. Zhang ZJ, Reynolds GP,. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55: 1-10.
21. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242.
22. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R,. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959; 81: 363-369.
23. Linn GS, Negi SS, Gerum SV, Javitt DC,. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 2003; 169: 234-239.
24. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162: 394-396.
25. Muir KW, Lees KR,. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503-513.
26. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270-276.
27. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303-309.
28. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-1107.
29. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-1015.
30. Kelley ME, Haas GL, van Kammen DP,. Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem. Schizophr Res 2008; 105: 188-196.
31. Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 11650-11655.
32. Brugger S, Davis JM, Leucht S, Stone JM,. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol Psychiatry 2011; 69: 495-503.
33. Steen RG, Hamer RM, Lieberman JA,. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949-1962.
34. Lymer K, Haga K, Marshall I, Sailasuta N, Wardlaw J,. Reproducibility of GABA measurements using 2D J-resolved magnetic resonance spectroscopy. Magn Reson Imaging 2007; 25: 634-640.
35. Choe BY, Kim KT, Suh TS, et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994; 1: 211-216.
36. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH,. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 31: 345-352.
37. Kegeles LS, Shungu DC, Anjilvel S, et al. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res 2000; 98: 163-175.
38. Galinska B, Szulc A, Tarasow E, et al. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit 2009; 15: CR82-CR88.
39. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R,. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998; 11: 266-272.
40. Goto N, Yoshimura R, Moriya J, et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 2009; 112: 192-193.
41. Ongur D, Prescot AP, McCarthy J, Cohen BM, Renshaw PF,. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry 2010; 68: 667-670.
42. Ongur D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF,. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 2009; 172: 44-48.
43. Tayoshi S, Nakataki M, Sumitani S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010; 117: 83-91.
44. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U,. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int 2007; 50: 291-301.
45. Omori M, Pearce J, Komoroski RA, et al. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol Psychiatry 1997; 42: 359-366.
46. Theberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-2233.
47. Theberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944-1946.
48. Olbrich HM, Valerius G, Rusch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 2008; 9: 59-63.
49. Tibbo P, Hanstock C, Valiakalayil A, Allen P,. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 1116-1118.
50. Theberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007; 191: 325-334.
51. Ohrmann P, Siegmund A, Suslow T, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005; 73: 153-157.
52. Reid MA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 2010; 68: 625-633.
53. Wood SJ, Yucel M, Wellard RM, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res 2007; 94: 328-331.
54. van Elst LT, Valerius G, Buchert M, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724-730.
55. Theberge J, Jensen JE, Rowland LM,. Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study". Biol Psychiatry 2007; 61: 1218-1219; author reply 1219-1220.
56. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K,. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 2007; 62: 1396-1404.
57. Yoo SY, Yeon S, Choi CH, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res 2009; 111: 86-93.
58. Toth E, Lajtha A,. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 1986; 11: 393-400.
59. Kanahara N, Shimizu E, Ohgake S, et al. Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) 2008; 198: 363-374.
60. Kaufman MJ, Prescot AP, Ongur D, et al. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res 2009; 173: 143-149.
61. Hashimoto K,. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010; 4: 10-19.
62. Pouwels PJ, Frahm J,. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed 1997; 10: 73-78.
63. Ghose S, Weickert CS, Colvin SM, et al. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 2004; 29: 117-125.
64. Nudmamud S, Reynolds LM, Reynolds GP,. N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol Psychiatry 2003; 53: 1138-1141.
65. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52: 829-836.
66. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP,. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res 2005; 73: 147-152.
67. Tsai SJ,. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med Sci Monit 2005; 11: HY39-HY45.
68. Choi C, Coupland NJ, Bhardwaj PP, Malykhin N, Gheorghiu D, Allen PS,. Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 Tesla. Magn Reson Med 2006; 55: 997-1005.
69. Hancu I,. Optimized glutamate detection at 3T. J Magn Reson Imaging 2009; 30: 1155-1162.
70. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C,. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med 2008; 60: 964-969.
71. Lebon V, Petersen KF, Cline GW, et al. Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 2002; 22: 1523-1531.
72. Hancu I, Port J,. The case of the missing glutamine. NMR Biomed 2011; 24: 529-535.
73. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959-965.
74. Shirayama Y, Obata T, Matsuzawa D, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010; 49: 2783-2790.
75. Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R,. In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 2001; 46: 451-456.
76. Ugurbil K, Adriany G, Andersen P, et al. Ultrahigh field magnetic resonance imaging and spectroscopy. Magn Reson Imaging 2003; 21: 1263-1281.
77. DeFelipe J,. Chandelier cells and epilepsy. Brain 1999; 122 (Pt 10): 1807-1822.
78. Doherty J, Dingledine R,. Regulation of excitatory input to inhibitory interneurons of the dentate gyrus during hypoxia. J Neurophysiol 1997; 77: 393-404.
79. Rodrigo R, Felipo V,. Control of brain glutamine synthesis by NMDA receptors. Front Biosci 2007; 12: 883-890.